Wink, your exclamation mark implies the spokesperson at CZM was...

Wink, your exclamation mark implies the spokesperson at CZM was surprised?

The CONVIVO doesn't fall into the 'consumer goods' category. When CONVIVO receives a CE Mark and FDA approval (and I say when, not if) public and private hospitals will need to commence a complex purchase process - business case, approval of budgets, board ratification, RFPs, etc.

If the board at Optiscan were to be charged with the task, I'd sell all my shares. But CZM do this for a living, they understand the process, will be going back to existing customers, selling a total solution that involves the CONVIVO, KINEVO, service agreements, etc - it all plays to their strengths.

The result will be a strong sales pipeline that will keep the people at Optiscan very busy. It may even see them scrambling.

It's been a long road, I'm not sure why everyone is expecting an overnight fix but the CE mark will see a flurry of activity and the end of the current buying opportunity. And yes, at $32m, I still think CZM may simplify things as far as patents and IP are concerned.

May the Fouth be with you all, and keep the faith.